269 related articles for article (PubMed ID: 30237801)
1. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
Front Immunol; 2018; 9():2027. PubMed ID: 30237801
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
[TBL] [Abstract][Full Text] [Related]
3. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
Front Immunol; 2019; 10():2129. PubMed ID: 31552054
[TBL] [Abstract][Full Text] [Related]
4. Noncatalytic Bruton's tyrosine kinase activates PLCγ
Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
[TBL] [Abstract][Full Text] [Related]
5. T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
Xia S; Liu X; Cao X; Xu S
Cell Mol Immunol; 2020 Oct; 17(10):1042-1052. PubMed ID: 31431692
[TBL] [Abstract][Full Text] [Related]
6. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
[TBL] [Abstract][Full Text] [Related]
9. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
10. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
11. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
[TBL] [Abstract][Full Text] [Related]
12. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
13. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells.
Tomlinson MG; Woods DB; McMahon M; Wahl MI; Witte ON; Kurosaki T; Bolen JB; Johnston JA
BMC Immunol; 2001; 2():4. PubMed ID: 11410123
[TBL] [Abstract][Full Text] [Related]
14. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
15. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
16. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Good L; Benner B; Carson WE
Cancer Immunol Immunother; 2021 Sep; 70(9):2439-2451. PubMed ID: 33818636
[TBL] [Abstract][Full Text] [Related]
18. Dual phosphorylation of Btk by Akt/protein kinase b provides docking for 14-3-3ζ, regulates shuttling, and attenuates both tonic and induced signaling in B cells.
Mohammad DK; Nore BF; Hussain A; Gustafsson MO; Mohamed AJ; Smith CI
Mol Cell Biol; 2013 Aug; 33(16):3214-26. PubMed ID: 23754751
[TBL] [Abstract][Full Text] [Related]
19. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
O'Riordan CE; Purvis GSD; Collotta D; Krieg N; Wissuwa B; Sheikh MH; Ferreira Alves G; Mohammad S; Callender LA; Coldewey SM; Collino M; Greaves DR; Thiemermann C
Front Immunol; 2020; 11():581758. PubMed ID: 33162995
[TBL] [Abstract][Full Text] [Related]
20. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
Rip J; de Bruijn MJW; Appelman MK; Pal Singh S; Hendriks RW; Corneth OBJ
Front Immunol; 2019; 10():95. PubMed ID: 30761150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
